Ed Zhang, MBA

Founding CEO

Ed Zhang is founding CEO of Overland Therapeutics. Immediately prior to Overland Therapeutics, Ed co-foundered its predecessor, Overland Pharma when he was a venture partner at Hillhouse Investment in 2020 and has served as CEO since 2022.

Ed brings over 20 years of biopharma industry experience, crossing scientific research, business development, strategy and general management. Before starting at Hillhouse, Ed was VP Corporate Development at Boston Pharmaceuticals as part of its initial founding team, leading corporate development and strategic initiatives. Prior to joining Boston Pharma, Ed headed global business development at Sanofi’s Specialty Products BU and was Director of Strategic Development at Genzyme before its acquisition by Sanofi. He started his career as a medicinal chemist at Pharmacia & Upjohn.

Ed holds B.S. from Nanjing University and M.B.A. from Kellogg School of Management at Northwestern University.

Hong Xie, MD, MBA

Chief Medical Officer

Dr. Xie serves as CMO of Overland Therapeutics.

Prior to joining Overland Therapeutics, Dr. Xie was the former Global Medical Head at Johnson & Johnson, where she led oncology medical strategy and played a key role in advancing global clinical development and medical affairs initiatives. She previously held multiple clinical development roles of increasing responsibility at leading pharmaceutical companies, including GSK, Merck & Co., and BeOne Medicines.

Dr. Xie brings more than 25 years of global pharmaceutical industry experience in the clinical development of innovative oncology, immunology, and hematology therapeutics, including hands-on diligence and business development achievements with in-licensing opportunities of $1B+ deal sizes.

Dr. Xie has a strong academic foundation, holding an M.D. in Medicine and an M.S. in Molecular Biology from Peking University, as well as an MBA from Lehigh University College of Business.

Xun Liu, PhD

Chief Technology Officer Advisor

Dr. Liu serves as CTO Advisor at Overland Therapeutics.

Dr. Liu will continue serving in his role as Senior Advisor at Hillhouse Investment, a position he has held to date. Prior to joining Overland and Hillhouse, Dr. Liu was the Vice President of Hengrui Medicine and the President of its Biomedicine Development and Business Division where he oversaw the development of over 50 new biological products, 23 of which entered clinical trials and 3 were approved for market launch. Previously, Dr. Liu was a tenured Staff Scientist at the Vaccine Research Center of the National Institutes of Health (NIH), where he was in charge of process development and clinical manufacturing of therapeutic and prophylactic vaccines. Prior to his role at the NIH, he was the Principal Engineer at Bayer HealthCare Pharmaceuticals, serving as Commercial Production Specialist for Kogenate®, Bayer’s top selling drug. Earlier in his career, he worked at Amgen and Vertex Pharmaceuticals in various drug development roles.

Dr. Liu earned a Bachelor of Science degree in chemistry from Beijing University and Ph.D. degree in biophysical chemistry from Rutgers University. Following his education, he was trained at Massachusetts Institute of Technology (MIT) as a post-doc fellow in the Nobel Laureate Professor Gobind Khorana’s laboratory for three and a half years.

John Maraganore, PhD

Strategic Advisor

Dr. John Maraganore serves as Strategic Advisor at Overland Therapeutics.

Prior to Overland, Dr. Maraganore served as the founding CEO and a Director of Alnylam from 2002 to 2021, where he built and led the company from early platform research on RNA interference through global approval and commercialization of the first four RNAi therapeutic medicines, ONPATTRO®, GIVLAARI®, OXLUMO®, and Leqvio®. At Alnylam, he also led the company’s value creation strategy, building $25B in market capitalization, including over 20 major pharmaceutical alliances. He continues to serve on the Alnylam Scientific Advisory Board. Prior to Alnylam, he served as an officer and a member of the management team for Millennium Pharmaceuticals, Inc., where he was responsible for the company’s product franchises in oncology, and cardiovascular, inflammatory and metabolic diseases, in addition to leadership of M&A, strategy, and biotherapeutics functions. Before Millennium, he served as Director of Molecular Biology and Director of Market and Business Development at Biogen, Inc. where he invented and led the discovery and development of ANGIOMAX® (bivalirudin) for injection. Previously, he was a scientist at ZymoGenetics, Inc. and the Upjohn Company.

Dr. Maraganore received his M.S. and Ph.D. in biochemistry and molecular biology at the University of Chicago. He is currently a Venture Partner at ARCH Venture Partners, a Venture Advisor at Atlas Ventures, and an Executive Partner at RTW Investments. He is also Chair of the Board of Directors of Hemab Therapeutics and a member of the Board of Directors of Agios Pharmaceuticals, Beam Therapeutics and the Biotechnology Industry Organization, where he was Chair from 2017-2019. In addition, he serves on the Board of the Termeer Foundation – committed to continuing the legacy of the late Henri A. Termeer, as Chair of the n-Lorem Foundation Advisory Council – committed to meeting the needs of patients with nano-rare diseases, and as a strategic advisor to SalioGen, SQZ Biotechnologies, and other innovative companies.

Peter Ho, MD, PhD

Strategic Advisor and Director

Dr. Peter Ho serves as Strategic Advisor and Director at Overland Therapeutics.

Dr. Ho’s career has focused on cancer drug discovery and development. He previously served as Chief Medical Officer at Boston Pharmaceuticals and Epizyme Inc. In these roles, he oversaw clinical development functional areas including medical, clinical operations, clinical pharmacology, regulatory affairs, translational medicine, biostatistics and data management. Prior, he was Co-Founder and President of BeiGene Ltd. located in Beijing, China. His prior leadership roles includes serving as Senior VP of oncology discovery at GlaxoSmithKline and VP of oncology development at Johnson & Johnson. Dr. Ho completed his pediatrics residency at The Children’s Hospital of Boston followed by clinical fellowships in pediatric hematology/oncology at the Dana-Farber Cancer Institute and in clinical oncology and regulatory sciences jointly through the U.S. Food and Drug Administration (FDA) and the National Cancer Institute. Since 1995, he has been responsible for the first-in-human dosing of 19 anticancer agents and has overseen the development of over 60 hematology and oncology compounds in clinical phases of testing, contributing to 11 NCE approvals to date: Gleevec®; Arranon®; Tykerb®; Promacta®; Votrient®; Synribo®; Tafinlar®; Mekinist®; Sylvant®; and Rydap®, and Tazverik®.

Dr. Ho earned his M.D. and Ph.D. in pharmacology from Yale University. He currently serves as Adjunct Associate Professor at the University of North Carolina’s Eshelman School of Pharmacy, a Scientific Advisory Board Member for Accent Therapeutics, and on the Board of Directors for Aravive Inc.